Ledipasvir - Isotope Labelled Standards
References
FAQ's
References
- Guo, Hongyan; Kato, Darryl; Kirschberg, Thorsten A.; Liu, Hongtao; Link, John O.; Mitchell, Michael L.; Parrish, Jay P.; Squires, Neil; Sun, Jianyu; Taylor, James; et al, Antiviral compounds, WO2010132601A1, Nov 18, 2010, Gilead Sciences, Inc., United States (https://patents.google.com/patent/WO2010132601A1/en)
- Devilal, J.; Durgaprasad, B.; Pal, Narottam; Rao, A. Srinivasa, New method development and validation for the determination of Ledipasvir in bulk drug form by using reverse phase HPLC technique, World Journal of Pharmacy and Pharmaceutical Sciences, Volume: 5, Issue: 8, Pages: 1312-1321, 2016 DOI: (10.20959/wjpps20168-7410)
Frequently Asked Questions
2.What is the analytical method to identify Ledipasvir impurities?
A reverse-phase high-performance liquid chromatography method helps identify Ledipasvir impurities.
3.What causes the degradation of the Ledipasvir drug?
Ledipasvir degrades under oxidative, alkaline, and acid conditions.
4.Which analytical technique identifies the Ledipasvir degradation products in the drug?
Ledipasvir degradation products are identified using the LC-MS/MS analytical method.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.